Erythropoietin receptor response circuits

Current Opinion in Hematology

Volumn 17, Issue 3, 2010, Pages 169-176

  Wojchowski, Don M ^a   Sathyanarayana, Pradeep ^a   Dev, Arvind ^a  

^a Maine Medical Center Research Institute   (United States)

Author keywords

Cytoprotection; Erythropoiesis; Erythropoiesis stimulating agents; Erythropoietin; Erythropoietin receptor

Indexed keywords

ADAPTOR PROTEIN; ANTIANEMIC AGENT; CNTO 528; CNTO 530; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PODOCALYXIN; PODOCALYXIN LIKE 1; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIBBLES 3 PROTEIN; UNCLASSIFIED DRUG;

CARCINOGENESIS; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; ERYTHROBLAST; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ERYTHROBLASTS; ERYTHROPOIETIN; HUMANS; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 77951463645     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328338008b     Document Type: Review

References (143)

1. Reissman K. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood 1950; 5:372-380.
2. Erslev A. Humoral regulation of red cell production. Blood 1953; 8:349-357.
3. Plzak LF, Fried W, Jacobson LO, Bethard WF. Demonstration of stimulation of erythropoiesis by plasma from anemic rats using Fe59. J Lab Clin Med 1955; 46:671-678.
4. Jacobson LO, Goldwasser E, Fried W, Plzak LF. Role of the kidney in erythropoiesis. Nature 1957; 179:633-634.
5. Stopka T, Zivny JH, Stopkova P, et al. Human hematopoietic progenitors express erythropoietin. Blood 1998; 91:3766-3772.
6. Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 2008; 105:6998-7003.
7. Tam BY, Wei K, Rudge JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006; 12:793-800.
8. Weidemann A, Kerdiles YM, Knaup KX, et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest 2009; 119:3373-3383.
9. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252:5558-5564.
10. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82:7580-7584.
11. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-78.
12. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 1989; 57:277-285.
13. D'Andrea AD, Yoshimura A, Youssoufian H, et al. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 1991; 11:1980-1987.
14. Quelle DE, Wojchowski DM. Localized cytosolic domains of the erythropoietin receptor regulate growth signaling and down-modulate responsiveness to granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 1991; 88:4801-4805.
15. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74:227-236.
16. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 2003; 12:1239-1250.
17. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87:6934-6938.
18. Metcalf D. Hematopoietic cytokines. Blood 2008; 111:485-491.
19. Wu H, Liu X, Jaenisch R, et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59-67.
20. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93:385-395.
21. Fried W. Erythropoietin and erythropoiesis. Exp Hematol 2009; 37:1007-1015.
22. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005; 15:146-155.
23. Constantinescu SN, Ghaffari S, Lodish HF. The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab 1999; 10:18-23.
24. Lu X, Gross AW, Lodish HF. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem 2006; 281:7002-7011.
25. Bunting KD. STAT5 signaling in normal and pathologic hematopoiesis. Front Biosci 2007; 12:2807-2820.
26. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293:90-95.
27. Arcasoy MO. The nonhaematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141:14-31.
28. Bahlmann FH, FliserD. Erythropoietin and renoprotection.CurrOpin Nephrol Hypertens 2009; 18:15-20.
29. Fliser D, Haller H. Erythropoietin and treatment of nonanemic conditions: cardiovascular protection. Semin Hematol 2007; 44:212-217.
30. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heterore-ceptor. Proc Natl Acad Sci USA 2004; 101:14907-14912.
31. Asaumi Y, Kagaya Y, Takeda M, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007; 115:2022-2032.
32. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008; 264:405-432.
33. Taoufik E, Petit E, Divoux D, et al. TNF receptor I sensitizes neurons to erythropoietin-and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci USA 2008; 105:6185-6190.
34. Schroder K, Kohnen A, Aicher A, et al. NADPH oxidase Nox2 is required for hypoxia-induced mobilization of endothelial progenitor cells. Circ Res 2009;105:537-544.
35. Sytkowski AJ. Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE 2007; 2007:e38.
36. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007; 356:2445-2448.
37. Crawford J. Erythropoietin: high profile, high scrutiny. J Clin Oncol 2007; 25:1021-1023.
38. Arcasoy MO. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin Cancer Res 2008; 14:4685-4690.
39. Tovari J, Pirker R, Timar J, et al. Erythropoietin in cancer: an update. Curr Mol Med 2008; 8:481-491.
40. Leyland-Jones B, and Group BIaS. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4:459-460. (Pubitemid 37009952)
41. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-1260.
42. Mohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005; 7:537-543.
43. Leo C, Horn LC, Rauscher C, et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 2006; 12:6894-6900.
44. Mohyeldin A, Dalgard CL, Lu H, et al. Survival and invasiveness of astrocytomas promoted by erythropoietin. J Neurosurg 2007; 106:338-350.
45. Phillips TM, Kim K, Vlashi E, et al. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007; 9:1122-1129.
46. Miller CP, Lowe KA, Valliant-Saunders K, et al. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells 2009; 27:2353-2361.
47. Bunn HF. New agents that stimulate erythropoiesis. Blood 2007; 109:868-873.
48. Perugini M, Varelias A, Sadlon T, et al. Hematopoietic growth factor mi-metics: from concept to clinic. Cytokine Growth Factor Rev 2009; 20:87-94.
49. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996; 273:464-471.
50. Johnson DL, Farrell FX, Barbone FP, et al. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 1997; 4:939-950.
51. Johnson DL, Farrell FX, Barbone FP, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 1998; 37:3699-3710.
52. Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007; 16:1649-1661.
53. McGahan L. Continuous erythropoietin receptor activator (Mircera) for renal anemia. Issues Emerg Health Technol 2008:1-6.
54. Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008; 9:839-849.
55. Duliege AM, Macdougall I, Duncan N, et al. Hematide, a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in a phase 2 single dose, dose escalating study in patients with chronic kidney disease (CKD) [abstract #3532]. Blood 2005; 106.
56. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006; 34:1303-1311.
57. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108:1830-1834.
58. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009; 361:1848-1855
59. Bouman-Thio E, Franson K, Miller B, et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008; 48:1197-1207.
60. Sathyanarayana P, Houde E, Marshall D, et al. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proery throblast pools. Blood 2009; 113:4955-4962.
61. Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007; 110:2140-2147.
62. Liu Z, Stoll VS, Devries PJ, et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 2007; 110:2408-2413.
63. Lacy SE, DeVries PJ, Xie N, et al. The potency of erythropoietin-mimic antibodies correlates inversely with affinity. J Immunol 2008; 181:1282-1287.
64. Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a\/\5b\/\mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98:181-191.
65. Klingmuller U, Wu H, Hsiao JG, et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci USA 1997; 94:3016-3021.
66. Haseyama Y, Sawada K, Oda A, et al. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood 1999; 94:1568-1577.
67. Wagner KU, Claudio E, Rucker EB3rd, et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000; 127:4949-4958.
68. Rhodes MM, Kopsombut P, Bondurant MC, et al. Bcl-x(L) prevents apoptosis of late-stage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin. Blood 2005; 106:1857-1863.
69. Sathyanarayana P, Dev A, Fang J, et al. EPO receptor circuits for primary erythroblast survival. Blood 2008; 111:5390-5399.
70. Fang J, Menon M, Kapelle W, et al. EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts. Blood 2007; 110:2361-2370.
71. Sathyanarayana P, Menon MP, Bogacheva O, et al. Erythropoietin modulation of podocalyxin and a proposed erythroblast niche. Blood 2007; 110:509-518.
72. Arcasoy MO, Karayal AF. Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain. Biochim Biophys Acta 2005; 1740: 17-28.
73. Maran J, Prchal J. Polycythemia and oxygen sensing. Pathol Biol (Paris) 2004; 52:280-284.
74. Menon MP, Fang J, Wojchowski DM. Core erythropoietin receptor signals for late erythroblast development. Blood 2006; 107:2662-2672.
75. Huddleston H, Tan B, Yang FC, et al. Functional p85alpha gene is required for normal murine fetal erythropoiesis. Blood 2003; 102:142-145.
76. Kuo YY, Chang ZF. GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription. Mol Cell Biol 2007; 27:4261-4272.
77. Maeda T, Ito K, Merghoub T, et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev Cell 2009; 17:527-540.
78. Dev A, Wojchowski DM. TRIB3 pseudokinase is induced via an EPO/EPOR/STAT5 pathway, markedly up-modulated in late-stage erythroblasts, and plays an essential non-redundant role during stress erythropoiesis [abstract #1985]. In: Proceedings of the ASH Annual Meeting Abstracts 2009.
79. Liu N, Phillips T, Zhang M, et al. Serine protease inhibitor 2A is a protective factor for memory T cell development. Nat Immunol 2004; 5:919-926. (Pubitemid 39276236)
80. Liu N, Wang Y, Ashton-Rickardt PG. Serine protease inhibitor 2A inhibits caspase-independent cell death. FEBS Lett 2004; 569:49-53. (Pubitemid 38844591)
81. Qi L, Heredia JE, Altarejos JY, et al. TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science 2006; 312:1763-1766.
82. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248:378-381.
83. Mayani H, Dragowska W, Lansdorp PM. Cytokine-induced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells. Blood 1993; 81:3252-3258.
84. Pless M, Norga K, Carroll M, et al. Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding. Blood 1997; 89:3175-3185.
85. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 2002; 21:3295-3313.
86. Robb L. Cytokine receptors and hematopoietic differentiation. Oncogene 2007; 26:6715-6723.
87. Stoffel R, ZieglerS, Ghilardi N, et al. Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. Proc Natl Acad Sci USA 1999; 96:698-702.
88. Palani S, Sarkar CA. Integrating extrinsic and intrinsic cues into a minimal model of lineage commitment for hematopoietic progenitors. PLoS Comput Biol 2009; 5:e1000518.
89. Mziaut H, Kersting S, Knoch KP, et al. ICA512 signaling enhances pancreatic beta-cell proliferation by regulating cyclins D through STATs. Proc Natl Acad Sci USA 2008; 105:674-679.
90. Friedrichsen BN, Richter HE, Hansen JA, et al. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. Mol Endocrinol 2003; 17:945-958.
91. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 2007; 26:224-233.
92. Villarino AV, Tato CM, Stumhofer JS, et al. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med 2007; 204:65-71.
93. Menon MP, KarurV, Bogacheva O, et al. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest 2006; 116:683-694.
94. Jeong JY, Hoxhaj G, Socha AL, et al. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 2009; 7:1150-1157.
95. Fu P, Jiang X, Arcasoy MO. Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun 2009; 379:696-701.
96. Rieger MA, Hoppe PS, Smejkal BM, et al. Hematopoietic cytokines caninstruct lineage choice. Science 2009; 325:217-218.
97. Sarrazin S, Mossadegh-Keller N, Fukao T, et al. MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. Cell 2009; 138:300-313.
98. Friedman AD. Transcriptional control of granulocyte and monocyte development. Oncogene 2007; 26:6816-6828.
99. Maltby S, Hughes MR, Zbytnuik L, et al. Podocalyxin selectively marks erythroid-committed progenitors during anemic stress but is dispensable for efficient recovery. Exp Hematol 2009; 37:10-18.
100. Doyonnas R, Nielsen JS, Chelliah S, et al. Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood 2005; 105:4170-4178.
101. Nielsen JS, McNagny KM. Novel functions of the CD34 family. J Cell Sci 2008; 121:3683-3692.
102. Eto N, Wada T, Inagi R, et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72:455-463.
103. Schiffer M, Park JK, Tossidou I, et al. Erythropoietin prevents diabetes-induced podocyte damage. Kidney Blood Press Res 2008; 31:411-415.
104. Iiyama M, Kakihana K, Kurosu T, et al. Reactive oxygen species generated by hematopoietic cytokines play roles in activation of receptor-mediated signaling and in cell cycle progression. Cell Signal 2006; 18:174-182.
105. Marinkovic D, Zhang X, Yalcin S, et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest 2007; 117:2133-2144.
106. Chen J, Connor KM, Aderman CM, et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008; 118:526-533.
107. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001; 412:641-647.
108. Huang X, Pierce LJ, Chen GL, et al. Erythropoietin receptor signaling regulates both erythropoiesis and megakaryopoiesis in vivo. Blood Cells Mol Dis 2010; 44:1-6.
109. Klimchenko O, Mori M, Distefano A, et al. A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood 2009; 114:1506-1517.
110. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001; 8:1327-1338.
111. Funakoshi-Tago M, Pelletier S, Moritake H, et al. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 2008; 28:1792-1801.
112. Hookham MB, Elliott J, Suessmuth Y, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007; 109:4924-4929.
113. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008; 19:414-422.
114. Haan S, WullerS, Kaczor J, et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene 2009; 28:3069-3080.
115. Boyle K, Zhang JG, Nicholson SE, et al. Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell Signal 2009; 21:394-404.
116. Tannahill GM, Elliott J, Barry AC, et al. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 2005; 25:9115-9126.
117. Kiu H, Greenhalgh CJ, Thaus A, et al. Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2. Growth Factors 2009; 27:384-393.
118. Quentmeier H, Geffers R, Jost E, et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 2008; 22:2169-2175.
119. Elliott J, Hookham MB, Johnston JA. The suppressors of cytokine signalling E3 ligases behave as tumour suppressors. Biochem Soc Trans 2008; 36:464-468.
120. Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 2008; 123:1586-1592.
121. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114:2764-2773.
122. Babon JJ, Sabo JK, Zhang JG, et al. The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression. J Mol Biol 2009; 387:162-174.
123. Piessevaux J, Lavens D, Peelman F, et al. The many faces of the SOCS box. Cytokine Growth Factor Rev 2008; 19:371-381.
124. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005; 105: 4604-4612.
125. Gery S, Cao Q, Gueller S, et al. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 2009; 85:957-965.
126. Buza-Vidas N, Antonchuk J, Qian H, et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev 2006; 20:2018-2023.
127. Gery S, Gueller S, Nowak V, et al. Expression of the adaptor protein Lnk in leukemia cells. Exp Hematol 2009; 37:585-592.
128. Werz C, Kohler K, Hafen E, et al. The Drosophila SH2B family adaptor Lnk acts in parallel to chico in the insulin signaling pathway. PLoS Genet 2009; 5:e1000596.
129. Wolfler A, Irandoust M, Meenhuis A, et al. Site-specific ubiquitination determines lysosomal sorting and signal attenuation of the granulocyte colony-stimulating factor receptor. Traffic 2009; 10:1168-1179.
130. Irandoust MI, Aarts LH, Roovers O, et al. Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. EMBO J 2007; 26:1782-1793.
131. Meyer L, Deau B, Forejtnikova H, et al. beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood 2007; 109:5215-5222.
132. Friedman AD, Nimbalkar D, Quelle FW. Erythropoietin receptors associate with a ubiquitin ligase, p33RUL, and require its activity for erythropoietin-induced proliferation. J Biol Chem 2003; 278:26851-26861.
133. Sulahian R, Cleaver O, Huang LJ. Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. Blood 2009; 113:5287-5297.
134. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythro-poietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469-475. (Pubitemid 34441737)
135. Bugelski PJ, Capocasale RJ, Makropoulos D, et al. CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 2008; 134:171-180.
136. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydro-xylation. Cell 2001; 107:43-54.
137. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-1340.
138. Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 2005; 338:617-626.
139. Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp 2006; 272:15-25; discussion 25-36.
140. Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 2009; 119:1159-1166.
141. Chan DA, KawaharaTL, Sutphin PD, et al. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009; 15:527-538.
142. Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 2007; 21:505-510.
143. Quelle DE, Quelle FW, Wojchowski DM. Mutations in the WSAWSE and cytosolic domains of the erythropoietin receptor affect signal transduction and ligand binding and internalization. Mol Cell Biol 1992; 12:4553-4561.